Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

43

Revenue 2017

Perjeta

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Perjeta was produced by Roche.

FDA panel backs Puma's breast cancer drug, with reservations

FDA panel backs Puma's breast cancer drug, with reservations trial of Herceptin plus Perjeta (pertuzumab), which if positive could end up replacing Herceptin alone as the go-to adjuvant therapy for HER2-positive breast cancer.

A new decade of disruption: meeting the biosimilar challgenge

A new decade of disruption: meeting the biosimilar challgenge High price tags have seen a string of rejections for routine NHS use by the UK watchdog NICE, including cancer MAbs Avastin (bevacizumab), Kadcyla (ado-trastuzumab emtansine) and Perjeta (pertuzumab).

Mylan deal with Roche clears path to biosimilar Herceptin launch

Mylan deal with Roche clears path to biosimilar Herceptin launch A recent forecast suggested Herceptin will be particularly resilient, still near-$4bn product in 2022, helped by combination use with Roche's newer HER2 drug Perjeta (pertuzumab) which grew 26% to

NICE backs Roche’s Perjeta for routine NHS use

NICE backs Roche’s Perjeta for routine NHS use Roche's Perjeta is on track to become the first new breast cancer drug available to NHS patients for nearly a decade after NICE backed it in draft guidance. ... Given in combination with Herceptin (trastuzumab) and docetaxel, Perjeta (pertuzumab) was

Roche in "unprecedented" launch period for new medicines

Roche in The star in Roche's show was once again its trio of HER2-positive breast cancer drugs - Herceptin (trastuzumab), Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine) - whose sales increased 9% to ... 12bn francs, driven mainly by a 31% growth for

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Why we need to improve diverse representation in clinical trials
Diversity in clinical trials: The powerful need to improve it! “One size fits all” is rapidly becoming an outdated concept in modern-day life, and medical research is no exception. Without...

Infographics